Showing 101 - 120 results of 33,497 for search '(( 50 ((nn decrease) OR (((teer decrease) OR (a decrease)))) ) OR ( 2 fold decrease ))', query time: 0.98s Refine Results
  1. 101
  2. 102
  3. 103
  4. 104

    ApoER2 expression increases Aβ production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulat... by Rodrigo A Fuentealba (77901)

    Published 2011
    “…<p><b>Copyright information:</b></p><p>Taken from "ApoER2 expression increases Aβ production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of γ-secretase activity"</p><p>http://www.molecularneurodegeneration.com/content/2/1/14</p><p>Molecular Neurodegeneration 2007;2():14-14.…”
  5. 105
  6. 106
  7. 107
  8. 108
  9. 109
  10. 110
  11. 111
  12. 112

    <i>tho2</i> and <i>hpr1</i> selectively decrease the expression level of Rif1p. by Tai-Yuan Yu (328952)

    Published 2013
    “…<p>(<b>A</b>) The Rif1p protein level is decreased in <i>tho2</i> and <i>hpr1</i> cells. Total yeast proteins from wild-type, <i>tho2</i> or <i>hpr1</i> yeast cells were precipitated with TCA, separated on an 8% SDS-polyacrylamide gel, and analyzed by immunoblotting using antibodies against Rap1p, Cdc13p, α-tubulin, α-actin, Myc (for myc9-tagged Rif1p and Rif2p), or TAP (for TAP-tagged Sir4p) (top panel). …”
  13. 113
  14. 114
  15. 115
  16. 116

    Aquaporin 2 Mutations in <i>Trypanosoma brucei gambiense</i> Field Isolates Correlate with Decreased Susceptibility to Pentamidine and Melarsoprol by Fabrice E. Graf (469055)

    Published 2013
    “…Here we describe two different kinds of <i>TbAQP2</i> mutations found in <i>T. b. gambiense</i> field isolates: simple loss of <i>TbAQP2</i>, or loss of wild-type <i>TbAQP2</i> allele combined with the formation of a novel type of <i>TbAQP2/3</i> chimera. …”
  17. 117
  18. 118
  19. 119
  20. 120

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”